LETTER: SA must improve ability to produce ARVs

Ensuring our country’s improved capacity to produce medicines and vaccines locally will remain a critical undertaking if we want to improve the lives of people with HIV at the global epicentre of the virus. 

To do so we must decrease our reliance on foreign imports and develop a sustainable pharmaceutical manufacturing framework that will remain dedicated to securing Africa’s supply of life-saving antiretrovirals (ARVs) over the long-term. 

To achieve medicine supply at this level the National Treasury must allocate 1% of SA’s GDP towards research, intellectual property development, product discovery and innovation in the healthcare sector. This will help provide SA scientists with the resources they require to develop their own intellectual property rights for the production of active pharmaceutical ingredients (API) and drug substances in our country.

The Joint UN Programme on HIV/Aids’ (UNAids’) “95-95-95” targets call for 95% of people living with HIV to be aware of their status, 95% of those aware of their status to be on ARV therapy, and 95% of those on therapy to achieve viral load suppression. The SA health department hopes to achieve these targets by 2030. At present, only 79% of those aware of their status are on antiretroviral therapy in SA.

Investing (locally) in healthcare facilities with the capacity to manufacture the drug substances and APIs associated with ARV and PrEP treatments will remain a significant undertaking to help SA meet these goals, while making medication more affordable and improving the security of supply in emerging markets across the continent today. 

Michael Mynhardt
Cofounder & CEO at MMH & Partners

JOIN THE DISCUSSION: Send us an email with your comments to letters@businesslive.co.za. Letters of more than 300 words will be edited for length. Anonymous correspondence will not be published. Writers should include a daytime telephone number.